Epsilogen Ltd

📍 Hammersmith, United Kingdom🗓 Founded 2016👥 29 employees💰 Last funded Mar 2022
Biotechnology🌐 epsilogen.com
Website LinkedIn
Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The companys lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the worlds first IgE therapeutic to enter the clinic.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Epsilogen Ltd?
Epsilogen Ltd has 1 investors on record on gritt.io and 1 late-stage investors.
When did Epsilogen Ltd last raise funding?
The most recent investment in Epsilogen Ltd recorded on gritt.io was in March 2022.
When was Epsilogen Ltd founded?
Epsilogen Ltd was founded in 2016.
What industry is Epsilogen Ltd in?
Epsilogen Ltd operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Epsilogen Ltd based?
Epsilogen Ltd is headquartered in Hammersmith, United Kingdom.